A Survey on Patients' Opinions of Alternative Drug Delivery Systems for the Treatment of Glaucoma in South-South Nigeria.

IF 0.5 Q4 OPHTHALMOLOGY
Middle East African Journal of Ophthalmology Pub Date : 2023-11-21 eCollection Date: 2022-10-01 DOI:10.4103/meajo.meajo_120_23
Chigozie I Echieh, Karl Mercieca, Ugochukwu A Eze, Constance Weber, Adedeji Akinyemi, Affiong A Ibanga, Chidiebere P Echieh
{"title":"A Survey on Patients' Opinions of Alternative Drug Delivery Systems for the Treatment of Glaucoma in South-South Nigeria.","authors":"Chigozie I Echieh, Karl Mercieca, Ugochukwu A Eze, Constance Weber, Adedeji Akinyemi, Affiong A Ibanga, Chidiebere P Echieh","doi":"10.4103/meajo.meajo_120_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Despite the human ocular surface being easily accessible, ocular drug delivery can be challenging. When applied improperly, topical medications, the most popular first-line treatment used to treat glaucoma, can have a very brief contact time with the ocular surface and may not have the desired therapeutic impact. Drug delivery devices are gadgets that can address some of these problems. This study aims to determine patients' opinions on ocular drug delivery devices used in the treatment of primary open-angle glaucoma (POAG).</p><p><strong>Methods: </strong>A pretested interviewer-administered questionnaire was used in a cross-sectional study of 115 POAG patients recruited from outpatient clinics in two Nigerian tertiary health institutions. Participants were asked about their understanding and acceptance of five Ocular drug delivery systems (ODD), namely drug-emitting contact lenses (CL), punctual plugs, subconjunctival injections, intracameral implants, and trabecular meshwork micro-stents, for the treatment of POAG.</p><p><strong>Results: </strong>Sixty (52.2%) participants, whose average age was 50 ± 9.8 years, were men. Self-pay was used for eye health treatments by 65% of participants. Of the participants, 68.7% admitted to using eye drops on their own. 57% of people were said to take their glaucoma medications consistently. CL and subconjunctival implants were seen to be most acceptable according to 39% and 30% of participants, respectively. Major factors determining the acceptability of ODD for POAG treatment were observed to be cost and effectiveness.</p><p><strong>Conclusion: </strong>Patients in our cohort who are being treated for POAG have a fairly positive attitude towards ODD. The prospective use of these devices for POAG treatment in Nigeria will depend on their efficacy and cost, as well as how ophthalmologists will weigh ODD options.</p>","PeriodicalId":18740,"journal":{"name":"Middle East African Journal of Ophthalmology","volume":"29 4","pages":"220-225"},"PeriodicalIF":0.5000,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10754114/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East African Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/meajo.meajo_120_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Despite the human ocular surface being easily accessible, ocular drug delivery can be challenging. When applied improperly, topical medications, the most popular first-line treatment used to treat glaucoma, can have a very brief contact time with the ocular surface and may not have the desired therapeutic impact. Drug delivery devices are gadgets that can address some of these problems. This study aims to determine patients' opinions on ocular drug delivery devices used in the treatment of primary open-angle glaucoma (POAG).

Methods: A pretested interviewer-administered questionnaire was used in a cross-sectional study of 115 POAG patients recruited from outpatient clinics in two Nigerian tertiary health institutions. Participants were asked about their understanding and acceptance of five Ocular drug delivery systems (ODD), namely drug-emitting contact lenses (CL), punctual plugs, subconjunctival injections, intracameral implants, and trabecular meshwork micro-stents, for the treatment of POAG.

Results: Sixty (52.2%) participants, whose average age was 50 ± 9.8 years, were men. Self-pay was used for eye health treatments by 65% of participants. Of the participants, 68.7% admitted to using eye drops on their own. 57% of people were said to take their glaucoma medications consistently. CL and subconjunctival implants were seen to be most acceptable according to 39% and 30% of participants, respectively. Major factors determining the acceptability of ODD for POAG treatment were observed to be cost and effectiveness.

Conclusion: Patients in our cohort who are being treated for POAG have a fairly positive attitude towards ODD. The prospective use of these devices for POAG treatment in Nigeria will depend on their efficacy and cost, as well as how ophthalmologists will weigh ODD options.

尼日利亚南部地区患者对治疗青光眼的替代给药系统的看法调查。
目的:尽管人的眼表很容易接触到,但眼部给药却很困难。局部用药是治疗青光眼最常用的一线疗法,如果使用不当,药物与眼表的接触时间会非常短,可能达不到预期的治疗效果。给药装置是可以解决其中一些问题的小工具。本研究旨在了解患者对用于治疗原发性开角型青光眼(POAG)的眼部给药装置的看法:方法:在一项横断面研究中,对从尼日利亚两家三级医疗机构门诊部招募的 115 名 POAG 患者进行了预先测试的访谈者管理问卷调查。调查询问了参与者对五种眼部给药系统(ODD)的了解和接受程度,这五种系统分别是用于治疗 POAG 的发光隐形眼镜(CL)、准时塞、结膜下注射、巩膜内植入物和小梁网状结构微支架:60名(52.2%)参与者为男性,平均年龄为(50±9.8)岁。65%的参与者使用自费方式进行眼健康治疗。68.7%的参与者承认自己使用眼药水。57%的人表示会坚持服用青光眼药物。分别有 39% 和 30% 的参与者认为 CL 和结膜下植入物最容易被接受。据观察,决定ODD治疗POAG可接受性的主要因素是成本和有效性:结论:在我们的队列中,接受 POAG 治疗的患者对 ODD 持相当积极的态度。在尼日利亚,这些设备能否用于 POAG 治疗将取决于其疗效和成本,以及眼科医生将如何权衡 ODD 选项。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
1
期刊介绍: The Middle East African Journal of Ophthalmology (MEAJO), published four times per year in print and online, is an official journal of the Middle East African Council of Ophthalmology (MEACO). It is an international, peer-reviewed journal whose mission includes publication of original research of interest to ophthalmologists in the Middle East and Africa, and to provide readers with high quality educational review articles from world-renown experts. MEAJO, previously known as Middle East Journal of Ophthalmology (MEJO) was founded by Dr Akef El Maghraby in 1993.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信